Published in Am J Hypertens on June 01, 2007
Effects of central arterial aging on the structure and function of the peripheral vasculature: implications for end-organ damage. J Appl Physiol (1985) (2008) 3.25
Arterial Stiffness and Wave Reflection: Biomarkers of Cardiovascular Risk. Artery Res (2009) 1.62
Pulse Decomposition Analysis of the digital arterial pulse during hemorrhage simulation. Nonlinear Biomed Phys (2011) 0.99
Pulse wave velocity is more closely associated with cardiovascular risk than augmentation index in the relatively low-risk population. Heart Vessels (2009) 0.92
Arterial wave reflection in HIV-infected and HIV-uninfected Rwandan women. AIDS Res Hum Retroviruses (2009) 0.90
Increased burden and severity of metabolic syndrome and arterial stiffness in treatment-naïve HIV+ patients from Cameroon. Vasc Health Risk Manag (2013) 0.88
Influence of the central-to-peripheral arterial stiffness gradient on the timing and amplitude of wave reflections. Hypertens Res (2016) 0.87
Segmental kidney volumes measured by dynamic contrast-enhanced magnetic resonance imaging and their association with CKD in older people. Am J Kidney Dis (2014) 0.83
Dissociation between central augmentation index and carotid-femoral pulse-wave velocity: when and why? Am J Hypertens (2007) 0.81
Effects of acute variation of dialysate calcium concentrations on arterial stiffness and aortic pressure waveform. Nephrol Dial Transplant (2009) 0.80
Correlation of pulse wave velocity with left ventricular mass in patients with hypertension once blood pressure has been normalized. Heart Int (2012) 0.80
The effects of a multiflavonoid supplement on vascular and hemodynamic parameters following acute exercise. Oxid Med Cell Longev (2011) 0.80
Arterial Stiffness Gradient. Pulse (Basel) (2015) 0.79
Central hemodynamics in prehypertension: effect of the β-adrenergic antagonist nebivolol. J Clin Hypertens (Greenwich) (2012) 0.79
Carotid arterial stiffness and risk of incident cerebral microbleeds in older people: the Age, Gene/Environment Susceptibility (AGES)-Reykjavik study. Arterioscler Thromb Vasc Biol (2015) 0.78
Investigating properties of the cardiovascular system using innovative analysis algorithms based on ensemble empirical mode decomposition. Comput Math Methods Med (2012) 0.77
Aortic Pulse Wave Analysis is not a surrogate for central arterial Pulse Wave Velocity. Exp Biol Med (Maywood) (2009) 0.77
Effect of cardiorespiratory fitness on acute inflammation induced increases in arterial stiffness in older adults. Eur J Appl Physiol (2013) 0.76
The effect of prebiotic supplementation with inulin on cardiometabolic health: Rationale, design, and methods of a controlled feeding efficacy trial in adults at risk of type 2 diabetes. Contemp Clin Trials (2015) 0.75
Older age is associated with greater central aortic blood pressure following the exercise stress test in subjects with similar brachial systolic blood pressure. Heart Vessels (2015) 0.75
The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA (2003) 97.28
Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension (2003) 63.78
Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med (2004) 19.42
Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med (2005) 12.46
Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med (2009) 12.44
Genome-wide association study of blood pressure and hypertension. Nat Genet (2009) 11.54
Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med (2011) 11.11
Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA (2004) 9.74
Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med (2004) 9.67
C-reactive protein levels and outcomes after statin therapy. N Engl J Med (2005) 9.47
Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med (2012) 9.46
Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med (2004) 9.13
Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet (2003) 8.12
AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation (2006) 8.01
Spironolactone for heart failure with preserved ejection fraction. N Engl J Med (2014) 7.48
Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. JAMA (2005) 7.35
Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. N Engl J Med (2005) 6.86
Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med (2008) 6.17
Aortic stiffness, blood pressure progression, and incident hypertension. JAMA (2012) 6.01
A sensitive cardiac troponin T assay in stable coronary artery disease. N Engl J Med (2009) 5.81
Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N Engl J Med (2010) 5.48
Effect of angiotensin receptor blockade and antihypertensive drugs on diastolic function in patients with hypertension and diastolic dysfunction: a randomised trial. Lancet (2007) 5.06
Red cell distribution width as a novel prognostic marker in heart failure: data from the CHARM Program and the Duke Databank. J Am Coll Cardiol (2007) 4.74
Clinical correlates and heritability of flow-mediated dilation in the community: the Framingham Heart Study. Circulation (2004) 4.73
Cross-sectional relations of digital vascular function to cardiovascular risk factors in the Framingham Heart Study. Circulation (2008) 4.69
Treatment of anemia with darbepoetin alfa in systolic heart failure. N Engl J Med (2013) 4.67
Azithromycin for the secondary prevention of coronary heart disease events: the WIZARD study: a randomized controlled trial. JAMA (2003) 4.44
Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation (2006) 3.85
Survival with cardiac-resynchronization therapy in mild heart failure. N Engl J Med (2014) 3.80
Red blood cell distribution width and mortality risk in a community-based prospective cohort. Arch Intern Med (2009) 3.73
Aortic diameter, wall stiffness, and wave reflection in systolic hypertension. Hypertension (2007) 3.68
Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomised, controlled clinical trial. Lancet (2005) 3.67
Genome-wide association study identifies six new loci influencing pulse pressure and mean arterial pressure. Nat Genet (2011) 3.40
Controversies in ventricular remodelling. Lancet (2006) 3.39
Heart failure. Lancet (2005) 3.33
Single versus combined blood pressure components and risk for cardiovascular disease: the Framingham Heart Study. Circulation (2008) 3.16
Predictors of mortality and morbidity in patients with chronic heart failure. Eur Heart J (2005) 3.09
Framingham Heart Study 100K Project: genome-wide associations for blood pressure and arterial stiffness. BMC Med Genet (2007) 3.04
6-min walk test provides prognostic utility comparable to cardiopulmonary exercise testing in ambulatory outpatients with systolic heart failure. J Am Coll Cardiol (2012) 3.03
Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation (2007) 2.95
Albuminuria in chronic heart failure: prevalence and prognostic importance. Lancet (2009) 2.79
Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. Circulation (2005) 2.78
Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials. Circulation (2004) 2.73
Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas. Circulation (2006) 2.68
Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program. J Am Coll Cardiol (2006) 2.68
Homocysteine-lowering and cardiovascular disease outcomes in kidney transplant recipients: primary results from the Folic Acid for Vascular Outcome Reduction in Transplantation trial. Circulation (2011) 2.62
AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update endorsed by the National Heart, Lung, and Blood Institute. J Am Coll Cardiol (2006) 2.57
Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. Ann Intern Med (2003) 2.47
Body mass index and prognosis in patients with chronic heart failure: insights from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Circulation (2007) 2.41
Prognostic value of B-Type natriuretic peptides in patients with stable coronary artery disease: the PEACE Trial. J Am Coll Cardiol (2007) 2.40
Effects of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failure. Circulation (2005) 2.39
Determinants of elevated pulse pressure in middle-aged and older subjects with uncomplicated systolic hypertension: the role of proximal aortic diameter and the aortic pressure-flow relationship. Circulation (2003) 2.36
Expanding the definition and classification of hypertension. J Clin Hypertens (Greenwich) (2005) 2.35
Effect of pravastatin on cardiovascular events in people with chronic kidney disease. Circulation (2004) 2.33
Longitudinal and circumferential strain rate, left ventricular remodeling, and prognosis after myocardial infarction. J Am Coll Cardiol (2010) 2.29
Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial. J Am Soc Nephrol (2005) 2.25
Prognostic implications of left ventricular mass and geometry following myocardial infarction: the VALIANT (VALsartan In Acute myocardial iNfarcTion) Echocardiographic Study. JACC Cardiovasc Imaging (2008) 2.24
Effect of antecedent hypertension and follow-up blood pressure on outcomes after high-risk myocardial infarction. Hypertension (2007) 2.22
Association of the Trp719Arg polymorphism in kinesin-like protein 6 with myocardial infarction and coronary heart disease in 2 prospective trials: the CARE and WOSCOPS trials. J Am Coll Cardiol (2008) 2.21
Heart failure clinics and outpatient management: review of the evidence and call for quality assurance. Eur Heart J (2004) 2.20
Relations of inflammatory biomarkers and common genetic variants with arterial stiffness and wave reflection. Hypertension (2008) 2.14
Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease. Circulation (2005) 2.13
Triple antihypertensive therapy with amlodipine, valsartan, and hydrochlorothiazide: a randomized clinical trial. Hypertension (2009) 2.12
Genetic variants associated with cardiac structure and function: a meta-analysis and replication of genome-wide association data. JAMA (2009) 2.10
Association between cardiac biomarkers and the development of ESRD in patients with type 2 diabetes mellitus, anemia, and CKD. Am J Kidney Dis (2011) 2.05
Left ventricular remodeling and ventricular arrhythmias after myocardial infarction. Circulation (2003) 2.03
Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design. Nephrol Dial Transplant (2009) 2.02
Renal function and effectiveness of angiotensin-converting enzyme inhibitor therapy in patients with chronic stable coronary disease in the Prevention of Events with ACE inhibition (PEACE) trial. Circulation (2006) 2.01
Recommendations for Improving and Standardizing Vascular Research on Arterial Stiffness: A Scientific Statement From the American Heart Association. Hypertension (2015) 2.01
Pathogenesis of sudden unexpected death in a clinical trial of patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. Circulation (2010) 2.00
Functionally competent cardiac stem cells can be isolated from endomyocardial biopsies of patients with advanced cardiomyopathies. Circ Res (2011) 1.98
Omapatrilat reduces pulse pressure and proximal aortic stiffness in patients with systolic hypertension: results of the conduit hemodynamics of omapatrilat international research study. Circulation (2002) 1.93
Mechanisms of cardiac arrhythmias and sudden death in transgenic rabbits with long QT syndrome. J Clin Invest (2008) 1.93
Liver function abnormalities and outcome in patients with chronic heart failure: data from the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. Eur J Heart Fail (2009) 1.93
Relation of brachial and digital measures of vascular function in the community: the Framingham heart study. Hypertension (2011) 1.90
Right ventricular dysfunction and risk of heart failure and mortality after myocardial infarction. J Am Coll Cardiol (2002) 1.87
Stroke in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia treated with Darbepoetin Alfa: the trial to reduce cardiovascular events with Aranesp therapy (TREAT) experience. Circulation (2011) 1.87
The 2012 Canadian hypertension education program recommendations for the management of hypertension: blood pressure measurement, diagnosis, assessment of risk, and therapy. Can J Cardiol (2012) 1.86
The 2013 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. Can J Cardiol (2013) 1.85
Brachial artery vasodilator function and systemic inflammation in the Framingham Offspring Study. Circulation (2004) 1.84